Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Verseon Corporation (VSN)

  Print      Mail a friend

Wednesday 15 November, 2017

Verseon Corporation

Verseon presents second anticoagulant candidate

RNS Number : 3822W
Verseon Corporation
15 November 2017

Press release                                                                                                                                     November 15, 2017

Verseon Corporation

("Verseon" or the "Company")

Second anticoagulation candidate for clinical trials presented at AHA 2017

Fremont, Calif.-Verseon, a technology-based pharmaceutical company employing a computer-driven platform to develop a diverse drug pipeline, presented a second development candidate for clinical trials from its anticoagulation program at the American Heart Association's (AHA) Scientific Sessions 2017, yesterday. VE-2851 shows excellent efficacy paired with low bleeding risk in preclinical testing and is expected to enter clinical trials in 2018.


The candidate potently inhibits thrombin and is highly selective against a panel of related serine proteases. VE-2851 also shows pharmacokinetics suitable for oral dosing and was well tolerated in a 14-day dose-range finding study. In preclinical efficacy models such as the arteriovenous shunt thrombosis model, the compound displayed comparable efficacy to marketed anticoagulants. Similar to Verseon's first development candidate VE-1902, which is expected to enter phase I trials in early 2018, VE-2851 likewise potently inhibits thrombosis, but does not disrupt platelet function. It shows 30-40‑fold weaker inhibition of thrombin-mediated platelet activation in vitro and allows up to 5-fold higher maximum platelet activation in vivo compared to current NOACs. This distinguishing feature of Verseon's anticoagulants provides a biological rationale for their improved hemostatic control and the resulting lower bleeding risk observed in preclinical bleeding time tests.


"We are excited to have two drug candidates heading to the clinic in 2018," said Dr. Anirban Datta, Verseon's Director of Discovery Biology, who presented the results at the AHA conference. "Both development candidates act as potent anticoagulants without disrupting platelet function. This may allow them to become the first anticoagulants suitable for long-term combination therapy with antiplatelet drugs, achieving a significantly reduced risk of both major adverse cardiovascular events and bleeding." 


The full AHA abstract is available on the conference website and will be published in Circulation. Dr. Datta's presentation will also be featured in Thrombosis.TV, a leading destination for venous and arterial thrombosis education, news, and expert opinion.



About Verseon's anticoagulation program

Verseon's potent, highly selective oral direct thrombin inhibitors have shown excellent efficacy in multiple preclinical studies, but do not disrupt platelet function. This unique feature could explain the low bleeding risk of these precision anticoagulants and makes them excellent candidates for use in long-term combination anticoagulant-antiplatelet therapy. Two development candidates are expected to enter clinical trials in 2018, one of which has also demonstrated very low renal clearance, a highly desirable property for patients with impaired kidney function.


About Verseon

Verseon Corporation (, AIM: VSN) is a technology-based pharmaceutical company that combines a proprietary, computational drug discovery platform with a comprehensive in-house chemistry and biology workflow to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology. The anticoagulation program is scheduled to enter phase I clinical trials in 2018.


For further information, please contact

Verseon Corporation

Tina Schlafly

+1 (510) 225 9000

Cenkos Securities (NOMAD and Joint Broker)

Neil McDonald / Beth McKiernan

 +44 (0) 20 7397 8900

Cantor Fitzgerald Europe (Joint Broker) 

Marc Milmo / Phil Davies / Callum Butterfield

+44 (0) 20 7894 7000

Mirabaud Securities LLP (Joint Broker)

Peter Krens

+44 (0) 20 7321 2508


For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisers)

Henry Harrison-Topham / Jamie Hooper

+44 (0) 20 7466 5000


For trade and pharma media enquiries, please contact

Vane Percy & Roberts

Simon Vane Percy

+44 (0) 1737 821 890


Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook," and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions, and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors.


This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t